Torrent Pharmaceuticals Limited

“Torrent Pharmaceuticals is a high-quality, prescription-driven branded-generic compounder with a durable India chronic-disease franchise, strong returns on capital (~30% ROE), and a de-levered balance sheet — but it trades at 63-66x earnings, implying annualized returns of only 7-9% even under generous assumptions, with no step-change catalyst to justify the premium over peers. The business deserves patient attention at a materially lower entry point (~35-40x forward earnings, INR 2,600-3,000), where the quality of the franchise would translate into genuinely attractive long-term returns.”